Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q34620678)

3 August 2017

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

3 August 2017

4

D Cunningham

1 reference

ESMO Guidelines Working Group

3 August 2017

series ordinal

6

object named as

ESMO Guidelines Working Group

1 reference

3 August 2017

1

A Okines

1 reference

3 August 2017

M Verheij

2

1 reference

3 August 2017

W Allum

series ordinal

3

1 reference

3 August 2017

A Cervantes

series ordinal

5

1 reference

3 August 2017

1 May 2010

1 reference

3 August 2017

1 reference

3 August 2017

21 Suppl 5

1 reference

3 August 2017

v50-4

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

3 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Gastric cancer: global pattern of the disease and an overview of environmental risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Epidemiology of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Optimal locoregional treatment in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

Follow-up of patients resected for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ164

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ164

1 reference

3 August 2017

1 reference